Literature DB >> 19877577

In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.

Joëlle Riond1, Stéphane Rodriguez, Marie-Laure Nicolau, Talal al Saati, Jean Edouard Gairin.   

Abstract

Cell surface expression of MHC class I molecules by tumor cells is determinant in the interplay between tumor cells and the immune system. Nevertheless, the mechanisms which regulate MHCI expression on tumor cells are not clear. We previously showed that immune innate cells from the spleen can regulate MHCI expression on MHCI(low) tumor cells. Here, using the murine model of B16 melanoma, we demonstrate that the MHCI status of tumor cells in vivo is regulated by the microenvironment. In subcutaneous grafts, induction of MHCI molecules on tumor cells is concomitant to the recruitment of lymphocytes and relies on an IFNgamma-mediated mechanism. gammadelta T and NK cells are essential to this regulation. A small proportion of tumor-infiltrating NK cells and gammadelta T cells were found to produce IFNgamma, suggesting a possible direct participation to the MHCI increase on the tumor cells upon tumor cell recognition. Depletion of gammadelta T cells increases the tumor growth rate, confirming their anti-tumoral role in our model. Taken together, our results demonstrate that in vivo, NK and gammadelta T cells play a dual role during the early growth of MHCI(low) tumor cells. In addition to controlling the growth of tumor cells, they contribute to modifying the immunogenic profile of residual tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19877577      PMCID: PMC2935763     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  49 in total

1.  Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis.

Authors:  Jessica Strid; Scott J Roberts; Renata B Filler; Julia M Lewis; Bernice Y Kwong; William Schpero; Daniel H Kaplan; Adrian C Hayday; Michael Girardi
Journal:  Nat Immunol       Date:  2008-01-06       Impact factor: 25.606

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.

Authors:  Naotaka Shibagaki; Mark C Udey
Journal:  Eur J Immunol       Date:  2003-04       Impact factor: 5.532

Review 4.  Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.

Authors:  K Tanaka; T Yoshioka; C Bieberich; G Jay
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

Review 5.  MHC class I antigens and immune surveillance in transformed cells.

Authors:  Natalia Aptsiauri; Teresa Cabrera; Angel Garcia-Lora; Miguel Angel Lopez-Nevot; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Int Rev Cytol       Date:  2007

6.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

7.  The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.

Authors:  M J Smyth; M Taniguchi; S E Street
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.

Authors:  Nicole Schwinn; Daria Vokhminova; Antje Sucker; Sonja Textor; Sandra Striegel; Iris Moll; Norman Nausch; Jochen Tuettenberg; Alexander Steinle; Adelheid Cerwenka; Dirk Schadendorf; Annette Paschen
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

Review 9.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Gamma delta T cells provide an early source of interferon gamma in tumor immunity.

Authors:  Yunfei Gao; Wancai Yang; Meng Pan; Eileen Scully; Michael Girardi; Leonard H Augenlicht; Joe Craft; Zhinan Yin
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  15 in total

Review 1.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

Review 2.  γδ T cells in cancer.

Authors:  Bruno Silva-Santos; Karine Serre; Håkan Norell
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

3.  B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis.

Authors:  Huimin Lu; Yanchao Ma; Mingyuan Wang; Jin Shen; Hongya Wu; Juntao Li; Nan Gao; Yanzheng Gu; Xueguang Zhang; Guangbo Zhang; Tongguo Shi; Weichang Chen
Journal:  Cancer Immunol Immunother       Date:  2020-10-29       Impact factor: 6.968

4.  An Antigen-Delivery Protein Nanoparticle Combined with Anti-PD-1 Checkpoint Inhibitor Has Curative Efficacy in an Aggressive Melanoma Model.

Authors:  Medea Neek; Jo Anne Tucker; Nina Butkovich; Edward L Nelson; Szu-Wen Wang
Journal:  Adv Ther (Weinh)       Date:  2020-10-01

Review 5.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

Review 6.  Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Authors:  Virginie Lafont; Françoise Sanchez; Emilie Laprevotte; Henri-Alexandre Michaud; Laurent Gros; Jean-François Eliaou; Nathalie Bonnefoy
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

7.  Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects.

Authors:  Balázs Besztercei; Tamás Vancsik; Anett Benedek; Enikő Major; Mbuotidem J Thomas; Csaba A Schvarcz; Tibor Krenács; Zoltán Benyó; Andrea Balogh
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 5.923

8.  The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity.

Authors:  Shin Foong Ngiow; Bianca von Scheidt; Andreas Möller; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

9.  ERAP1/ERAP2 and RUNX3 polymorphisms are not associated with ankylosing spondylitis susceptibility in Chinese Han.

Authors:  W Su; L Du; S Liu; J Deng; Q Cao; G Yuan; A Kijlstra; P Yang
Journal:  Clin Exp Immunol       Date:  2018-03-30       Impact factor: 4.330

Review 10.  γδ T cells in cancer: a small population of lymphocytes with big implications.

Authors:  Mathilde Raverdeau; Stephen P Cunningham; Cathal Harmon; Lydia Lynch
Journal:  Clin Transl Immunology       Date:  2019-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.